NASDAQ:TBPH - Theravance Biopharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Theravance Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $26.13 -0.31 (-1.17 %) (As of 01/22/2020 01:21 PM ET) Add Compare Today's Range$25.51Now: $26.13▼$26.5650-Day Range$20.72MA: $23.87▼$26.4452-Week Range$15.18Now: $26.13▼$28.44Volume9,048 shsAverage Volume213,428 shsMarket Capitalization$1.48 billionP/E RatioN/ADividend YieldN/ABeta1.85 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TBPH Previous SymbolNASDAQ:TBPHV CUSIPN/A CIK1583107 Webhttp://www.theravance.com/ Phone650-808-6000Debt Debt-to-Equity RatioN/A Current Ratio3.27 Quick Ratio3.27Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$60.37 million Price / Sales24.57 Cash FlowN/A Price / Cash FlowN/A Book Value($0.93) per share Price / Book-28.10Profitability EPS (Most Recent Fiscal Year)($3.99) Net Income$-215,520,000.00 Net Margins-370.54% Return on EquityN/A Return on Assets-43.57%Miscellaneous Employees363 Outstanding Shares56,760,000Market Cap$1.48 billion Next Earnings Date2/25/2020 (Estimated) OptionableOptionable Receive TBPH News and Ratings via Email Sign-up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:TBPH Rates by TradingView Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions What is Theravance Biopharma's stock symbol? Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH." How were Theravance Biopharma's earnings last quarter? Theravance Biopharma Inc (NASDAQ:TBPH) released its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($1.05) EPS for the quarter, meeting the Zacks' consensus estimate of ($1.05). The biopharmaceutical company earned $12.43 million during the quarter, compared to the consensus estimate of $13.33 million. View Theravance Biopharma's Earnings History. When is Theravance Biopharma's next earnings date? Theravance Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Theravance Biopharma. What price target have analysts set for TBPH? 4 brokers have issued twelve-month target prices for Theravance Biopharma's shares. Their forecasts range from $18.00 to $55.00. On average, they anticipate Theravance Biopharma's share price to reach $35.75 in the next year. This suggests a possible upside of 36.9% from the stock's current price. View Analyst Price Targets for Theravance Biopharma. What is the consensus analysts' recommendation for Theravance Biopharma? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Theravance Biopharma. What are Wall Street analysts saying about Theravance Biopharma stock? Here are some recent quotes from research analysts about Theravance Biopharma stock: 1. Cantor Fitzgerald analysts commented, ". We believe it is a good time to take another look at TBPH given its inexpensive valuation, and ahead of important catalysts this year. We also note that TBPH’s cash and equivalents totaled $517.1MM as of 12/31/18. It appears well-positioned to receive over $1B in milestones and payments, but its market cap is only ~$1.3B. Therefore, we think the peak sales potential of TBPH’s organ-selective Trelegy, are all underappreciated. Our positive investment thesis supports our OW rating and 12-month PT of $55." (4/12/2019) 2. According to Zacks Investment Research, "Theravance reported narrower-than-expected loss in Q4. Also, revenues beat estimates. The company received a huge boost when the FDA approved Yupelri, the first once daily nebulized LAMA option for COPD, in November. Formal launch activities of Yupelri are currently underway. Meanwhile, the agreement to divest its only marketed drug, Vibativ, will enable Theravance to focus solely on the launch efforts of Yupelri. Moreover, its pipeline programs target highly competitive therapeutic areas. The company's collaboration agreements are a consistent source of funds. However, any agreement termination might be a huge setback for the company as was the case in the past. Shares of the company have underperformed the industry so far this year." (3/13/2019) Has Theravance Biopharma been receiving favorable news coverage? News headlines about TBPH stock have trended negative on Wednesday, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Theravance Biopharma earned a daily sentiment score of -2.3 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Theravance Biopharma. Are investors shorting Theravance Biopharma? Theravance Biopharma saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 2,640,000 shares, a decrease of 5.4% from the December 15th total of 2,790,000 shares. Based on an average trading volume of 309,100 shares, the days-to-cover ratio is currently 8.5 days. Approximately 6.9% of the company's shares are sold short. View Theravance Biopharma's Current Options Chain. Who are some of Theravance Biopharma's key competitors? Some companies that are related to Theravance Biopharma include Arrowhead Pharmaceuticals (ARWR), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Evotec (EVTCY), Allakos (ALLK), United Therapeutics (UTHR), Blueprint Medicines (BPMC), SAGE Therapeutics (SAGE), Nektar Therapeutics (NKTR), HUTCHISON CHINA/S (HCM), Mirati Therapeutics (MRTX), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Deciphera Pharmaceuticals (DCPH) and Ultragenyx Pharmaceutical (RARE). What other stocks do shareholders of Theravance Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Bausch Health Companies (BHC), Gilead Sciences (GILD), Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Immunomedics (IMMU), SCYNEXIS (SCYX), Johnson & Johnson (JNJ), Corbus Pharmaceuticals (CRBP), GW Pharmaceuticals PLC- (GWPH) and Progenics Pharmaceuticals (PGNX). Who are Theravance Biopharma's key executives? Theravance Biopharma's management team includes the folowing people: Mr. Rick E. Winningham, Chairman & CEO (Age 59)Mr. Bradford J. Shafer, Exec. VP, Gen. Counsel & Sec. (Age 59)Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A., Sr. VP of Corp. Devel. & Strategy (Age 46)Dr. Brett K. Haumann, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 49)Mr. Vijay Sabesan, Sr. VP of Technical Operations Who are Theravance Biopharma's major shareholders? Theravance Biopharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Nisa Investment Advisors LLC (0.01%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Burton G Malkiel, Donal O'connor, Philip D Worboys, Renee D Gala, Sharathchandra S Hegde and Vijay Sabesan. View Institutional Ownership Trends for Theravance Biopharma. Which major investors are selling Theravance Biopharma stock? TBPH stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC. Company insiders that have sold Theravance Biopharma company stock in the last year include Donal O'connor, Sharathchandra S Hegde and Vijay Sabesan. View Insider Buying and Selling for Theravance Biopharma. How do I buy shares of Theravance Biopharma? Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Theravance Biopharma's stock price today? One share of TBPH stock can currently be purchased for approximately $26.12. How big of a company is Theravance Biopharma? Theravance Biopharma has a market capitalization of $1.48 billion and generates $60.37 million in revenue each year. The biopharmaceutical company earns $-215,520,000.00 in net income (profit) each year or ($3.99) on an earnings per share basis. Theravance Biopharma employs 363 workers across the globe.View Additional Information About Theravance Biopharma. What is Theravance Biopharma's official website? The official website for Theravance Biopharma is http://www.theravance.com/. How can I contact Theravance Biopharma? Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected] MarketBeat Community Rating for Theravance Biopharma (NASDAQ TBPH)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 265 (Vote Outperform)Underperform Votes: 299 (Vote Underperform)Total Votes: 564MarketBeat's community ratings are surveys of what our community members think about Theravance Biopharma and other stocks. Vote "Outperform" if you believe TBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBPH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/22/2020 by MarketBeat.com StaffFeatured Article: Asset Allocation, Balancing Your Investments
